F Verrecchia

Summary

Country: France

Publications

  1. ncbi Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis
    Franck Verrecchia
    INSERM U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, Paris, France
    Autoimmun Rev 5:563-9. 2006
  2. ncbi [Functional interactions between the TGF-beta signaling pathway via the Smads and TNF-alpha: implications for the regulation of type I collagen expression]
    Franck Verrecchia
    INSERM U697, Hopital Saint Louis, Pavillon Bazin, 1, avenue Claude Vellefaux, 75010 Paris
    J Soc Biol 199:329-36. 2005
  3. ncbi Skin involvement in scleroderma--where histological and clinical scores meet
    F Verrecchia
    INSERM U697, Paris, France
    Rheumatology (Oxford) 46:833-41. 2007
  4. ncbi Transforming growth factor-beta and fibrosis
    Franck Verrecchia
    INSERM U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, Paris 75010, France
    World J Gastroenterol 13:3056-62. 2007
  5. ncbi Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner
    F Verrecchia
    INSERM, U532, , 75010 Paris, France
    Oncogene 20:3332-40. 2001
  6. ncbi [Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases?]
    J Larghero
    Unité de Thérapie Cellulaire, Hopital Saint Louis, AP HP, Paris, France
    Rev Med Interne 30:287-99. 2009
  7. ncbi Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis
    F Verrecchia
    INSERM U532, Hopital Saint-Louis, Paris, France; INSERM U489, , Paris, France
    J Invest Dermatol 116:755-63. 2001
  8. ncbi Downregulation of human type VII collagen (COL7A1) promoter activity by dexamethasone. Identification of a glucocorticoid receptor binding region
    M P Gras
    INSERM U532, H pital Saint Louis, Paris, France
    Exp Dermatol 10:28-34. 2001
  9. ncbi Distinct involvement of the Jun-N-terminal kinase and NF-kappaB pathways in the repression of the human COL1A2 gene by TNF-alpha
    Franck Verrecchia
    INSERM U532, Institut de Recherche sur la Peau, Hopital Saint Louis, Pavillon Bazin, 75010 Paris, France
    EMBO Rep 3:1069-74. 2002
  10. ncbi Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes
    L Vija
    INSERM U697, Paris, France
    Diabetes Metab 35:85-93. 2009

Collaborators

Detail Information

Publications36

  1. ncbi Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis
    Franck Verrecchia
    INSERM U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, Paris, France
    Autoimmun Rev 5:563-9. 2006
    ..Potential implications for the development of therapeutic approaches against tissue fibrosis during SSc are discussed...
  2. ncbi [Functional interactions between the TGF-beta signaling pathway via the Smads and TNF-alpha: implications for the regulation of type I collagen expression]
    Franck Verrecchia
    INSERM U697, Hopital Saint Louis, Pavillon Bazin, 1, avenue Claude Vellefaux, 75010 Paris
    J Soc Biol 199:329-36. 2005
    ..This review focuses on transcriptional regulation of type I collagen by TGF-beta and TNF-alpha, and on the molecular mechanisms that control the antagonistic activity of TNF-alpha against TGF-beta-driven type I collagen gene expression...
  3. ncbi Skin involvement in scleroderma--where histological and clinical scores meet
    F Verrecchia
    INSERM U697, Paris, France
    Rheumatology (Oxford) 46:833-41. 2007
    ....
  4. ncbi Transforming growth factor-beta and fibrosis
    Franck Verrecchia
    INSERM U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, Paris 75010, France
    World J Gastroenterol 13:3056-62. 2007
    ..This review focuses on the mechanisms underlying Smad modulation of fibrillar collagen expression and how it relates to fibrotic processes...
  5. ncbi Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner
    F Verrecchia
    INSERM, U532, , 75010 Paris, France
    Oncogene 20:3332-40. 2001
    ....
  6. ncbi [Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases?]
    J Larghero
    Unité de Thérapie Cellulaire, Hopital Saint Louis, AP HP, Paris, France
    Rev Med Interne 30:287-99. 2009
    ..Phase I-II studies are in progress in various countries to investigate the potential benefit from MSC due to their immunosuppressive properties, as an adjunctive therapy for severe refractory autoimmune disease...
  7. ncbi Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis
    F Verrecchia
    INSERM U532, Hopital Saint-Louis, Paris, France; INSERM U489, , Paris, France
    J Invest Dermatol 116:755-63. 2001
    ..These results indicate that targeting Sp1 efficiently blocks extracellular matrix gene expression, and suggest that such an approach may represent an interesting therapeutic alternative toward the treatment of fibrotic disorders...
  8. ncbi Downregulation of human type VII collagen (COL7A1) promoter activity by dexamethasone. Identification of a glucocorticoid receptor binding region
    M P Gras
    INSERM U532, H pital Saint Louis, Paris, France
    Exp Dermatol 10:28-34. 2001
    ....
  9. ncbi Distinct involvement of the Jun-N-terminal kinase and NF-kappaB pathways in the repression of the human COL1A2 gene by TNF-alpha
    Franck Verrecchia
    INSERM U532, Institut de Recherche sur la Peau, Hopital Saint Louis, Pavillon Bazin, 75010 Paris, France
    EMBO Rep 3:1069-74. 2002
    ..These results represent the first demonstration of an alternate usage of distinct signaling pathways by TNF-alpha to inhibit the expression of a given gene, COL1A2, depending on its activation state...
  10. ncbi Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes
    L Vija
    INSERM U697, Paris, France
    Diabetes Metab 35:85-93. 2009
    ..In this review, we provide a brief characterization of MSC immunomodulatory effects, and present the current experimental evidence for the potential therapeutic efficacy of MSC transplantation in diabetes...
  11. ncbi Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells
    J Berrou
    INSERM U702, Hopital Tenon AP HP, Paris, France
    Int J Mol Med 23:513-20. 2009
    ..Inhibition of AGE receptors or neutralization of the protease inhibitors TIMP-3 and PAI-1 could represent an important new therapeutic strategy for diabetic nephropathy...
  12. ncbi Tumor necrosis factor-alpha inhibits transforming growth factor-beta /Smad signaling in human dermal fibroblasts via AP-1 activation
    F Verrecchia
    INSERM U532, Hopital Saint Louis, 75010 Paris and INSERM U482, Hopital Saint Antoine, 75012 Paris, France
    J Biol Chem 275:30226-31. 2000
    ..In addition, Jun members compete with Smad3 for the common transcription co-activator p300. These two mechanisms are likely to act in concert to decrease Smad-specific transcription...
  13. ncbi [Involvement of TGFbeta1 in fibrotic diseases: role of its effectors, the Smad proteins]
    S Dennler
    INSERM U697, Institut de Recherche sur la Peau, pavillon Equerre Bazin, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France
    Rev Med Interne 27:46-9. 2006
    ..Transforming Growth Factor beta 1 (TGFbeta1) is a key cytokine in the development of fibrotic diseases which are characterized by a pathological excess of extracellular matrix involving multiple organs...
  14. ncbi [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?]
    F Verrecchia
    INSERM U957 EA3822, Faculte de Medecine, 1 rue Gaston Veil, Nantes Cedex, France
    Rev Med Interne 30:955-62. 2009
    ....
  15. ncbi NOVH increases MMP3 expression and cell migration in glioblastoma cells via a PDGFR-alpha-dependent mechanism
    M Laurent
    NSERM U515, Prolifération, Différenciation et Processus tumoraux bâtiment Kourilsky, Hopital Saint Antoine, 184 rue du Fbg St Antoine, 75012 Paris, France
    FASEB J 17:1919-21. 2003
    ..Thus, expression of NOVH in glioblastoma cells triggers a cascade of gene expression resulting in increased cell adhesion and migration...
  16. ncbi Evidence of an antifibrotic effect of immunosuppressive drugs: applications in the treatment of systemic sclerosis
    Franck Verrecchia
    INSERM U697, , 1 avenue Claude Vellefaux, 75010 Paris, France
    Expert Rev Clin Immunol 5:35-43. 2009
    ..Since 1996, this drug has been used at higher doses for autologous hematopoietic stem cell transplantations, permitting rapid and durable clinical and histological regression of skin fibrosis...
  17. ncbi Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis
    J Larghero
    Cell Therapy Unit, Assistance Publique Hopitaux de Paris, Saint Louis Hospital, Paris, France
    Ann Rheum Dis 67:443-9. 2008
    ..Mesenchymal stem cells (MSCs) have a potential immunomodulatory role in autoimmune disease; however, the qualitative properties and haematopoietic support capacity of MSCs derived from patients with autoimmune disease is unclear...
  18. ncbi TNF-alpha represses connexin43 expression in HaCat keratinocytes via activation of JNK signaling
    Chalotte Tacheau
    INSERM U697, Paris, France
    J Cell Physiol 216:438-44. 2008
    ..Together, these results identify JNK and not NFkappaB, as a critical mediator of TNF-alpha repressory effect on Cx43 gene expression...
  19. ncbi TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression
    Franck Verrecchia
    INSERM U532, Institut de Recherche sur la Peau, Pavillon Bazin, , 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Cell Signal 16:873-80. 2004
    ..This review focuses on transcriptional regulation of type I collagen by TGF-beta and TNF-alpha and on the molecular mechanisms that control the antagonistic activity of TNF-alpha against TGF-beta-driven type I collagen gene expression...
  20. ncbi Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?
    Nicolas Poulalhon
    INSERM U697, , 75010 Paris, France
    J Biol Chem 281:33045-52. 2006
    ..It thus appears that rapamycin may exert direct antifibrotic activities independent from its immunosuppressive action...
  21. ncbi [Cytokines in systemic sclerosis]
    J Baraut
    Inserm U 976, hôpital Saint Louis pavillon Bazin, 1, Avenue C Vellefaux, 75010 Paris, France
    Pathol Biol (Paris) 60:127-39. 2012
    ..The restoration of the Th1/Th2/Th17/Treg balance will contribute to the effectiveness of treatment and the use of cytokine modulators may therefore be considered in developing new therapeutic approaches...
  22. ncbi Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing
    Delphine Javelaud
    INSERM U532, Institut de Recherche sur la Peau, Universite Paris VII, Hopital Saint Louis, Pavillon Bazin, France
    J Biol Chem 278:24624-8. 2003
    ..Together these results demonstrate discrete, yet significant and highly specific, regulation of fibroblast functions important for wound healing by basal JNK activity...
  23. ncbi Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation
    Sylviane Dennler
    INSERM, U697, Universite Paris Diderot, 75010 Paris, France
    J Biol Chem 284:31523-31. 2009
    ..This region harbors SMAD and lymphoid enhancer factor/T cell factor binding sites that allow functional cooperation between SMAD3 and beta-catenin, recruited to the promoter in response to TGF-beta to drive GLI2 gene transcription...
  24. ncbi The steroid receptor co-activator-1 (SRC-1) potentiates TGF-beta/Smad signaling: role of p300/CBP
    Sylviane Dennler
    INSERM U697, Institut de Recherche sur la Peau, Hopital Saint Louis, Paris, France
    Oncogene 24:1936-45. 2005
    ..Smad3 interactions. These results identify SRC-1 as a novel Smad3/4 transcriptional partner, facilitating the functional link between Smad3 and p300/CBP...
  25. ncbi Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation
    Franck Verrecchia
    INSERM U532, Institut de Recherche sur la Peau, , Paris, France
    J Invest Dermatol 118:211-5. 2002
    ..Potential implications for the development of therapeutic approaches against tissue fibrosis are discussed...
  26. ncbi Control of connective tissue gene expression by TGF beta: role of Smad proteins in fibrosis
    Franck Verrecchia
    INSERM U532, Institut de Recherche sur la Peau, Pavillon Bazin, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France
    Curr Rheumatol Rep 4:143-9. 2002
    ..Their role in the modulation of extracellular matrix gene expression is discussed in this review...
  27. ncbi Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling
    Olivier Ferrigno
    INSERM U532, Institut de Recherche sur la Peau, Hopital Saint Louis, Paris, France
    Oncogene 21:4879-84. 2002
    ..Together, these data provide the first evidence that YAP65 is a Smad7 partner that facilitates the recruitment of the latter to activated TbetaRI, and enhances the inhibitory activity of Smad7 against TGF-beta signaling...
  28. ncbi Involvement of ERK signaling in halofuginone-driven inhibition of fibroblast ability to contract collagen lattices
    Charlotte Tacheau
    INSERM U697, 1 avenue Claude Vellefaux, 75010 Paris, France
    Eur J Pharmacol 573:65-9. 2007
    ..These data thus indicate that the inhibitory effect of halofuginone on fibroblast contractile activity, a key function for wound healing implicated in the development of tissue fibrosis, is an ERK-mediated mechanism...
  29. ncbi Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner
    Valérie Pendaries
    INSERM U532, Universite Paris VII, Institut de Recherche sur la Peau, Pavillon Bazin, Hopital Saint Louis, 1, avenue Claude Vellefaux, F 75475 Paris Cedex 10, France
    Oncogene 22:8212-20. 2003
    ....
  30. ncbi 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation
    Jeanne Wendling
    INSERM U532, Institut de Recherche sur la Peau, Pavillon Bazin, , 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Mol Pharmacol 64:707-13. 2003
    ..We thus provide a molecular explanation to the observed clinical benefits of 5-FU in the treatment of keloids and hypertrophic scars...
  31. ncbi In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil
    Nina Roos
    Institut National de la Santé et de la Recherche Médicale U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, 75010 Paris, France
    J Pharmacol Exp Ther 321:583-9. 2007
    ..g., collagen production, extracellular matrix contraction, and cell migration. Such properties may contribute to the beneficial therapeutic effects of MMF against fibrotic lesions developing in systemic sclerosis or during GVHD...
  32. ncbi c-Fos accelerates hepatocyte conversion to a fibroblastoid phenotype through ERK-mediated upregulation of paxillin-Serine178 phosphorylation
    Meryem C Güller
    INSERM U697, Universite Paris 7 Denis Diderot, Paris, France
    Mol Carcinog 48:532-44. 2009
    ..Since c-Fos is frequently overexpressed in hepatocarcinomas, this newly identified mechanism might be involved in the progression of hepatic tumors in vivo...
  33. ncbi Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo
    Sylviane Dennler
    INSERM U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, 75010 Paris, France
    Cancer Res 67:6981-6. 2007
    ..We thus identify TGF-beta as a potent transcriptional inducer of Gli transcription factors. Targeting the cooperation of Hh and TGF-beta signaling may provide new therapeutic opportunities for cancer treatment...
  34. ncbi TGF-beta induces connexin43 gene expression in normal murine mammary gland epithelial cells via activation of p38 and PI3K/AKT signaling pathways
    Charlotte Tacheau
    INSERM U697, Paris, France
    J Cell Physiol 217:759-68. 2008
    ....
  35. ncbi Extracellular matrix metalloproteinase inducer/CD147 promotes myofibroblast differentiation by inducing alpha-smooth muscle actin expression and collagen gel contraction: implications in tissue remodeling
    Eric Huet
    CRRET Laboratory, CNRS UMR 7149, University Paris XII, 61 av du General de Gaulle, 94010 Creteil Cedex, France
    FASEB J 22:1144-54. 2008
    ..These findings, combined with the fact that EMMPRIN and alphaSMA colocalized to the same cells in the stroma of pathological corneas, expand on the mechanism by which EMMPRIN remodels extracellular matrix during wound healing and cancer...
  36. ncbi A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression
    Franck Verrecchia
    INSERM U532, Institut de Recherche sur la Peau Hôpital Saint Louis, 75475 Paris Cedex 10, France
    J Biol Chem 278:1585-93. 2003
    ..In addition, we demonstrate that such a JNK-dependent regulatory mechanism underlies the antagonistic activity of TNF-alpha against TGF-beta-induced up-regulation of type I and III collagens in fibroblasts...